NRG Oncology Clinical Trial: NRG-LU005

Limited-Stage Small Cell Lung Cancer (LS-SCLC): A Phase II/III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab

About the trial
NRG-LU005 is a clinical trial that is studying if adding the immunotherapy drug atezolizumab to the usual treatment of chemoradiotherapy can help lower the chance of small cell lung cancer growing or spreading. Immunotherapy drugs improve a person’s ability to fight infection and disease. Although the usual chemoradiotherapy treatment for this type of cancer does shrink the tumor in most cases, patients typically relapse quickly. Researchers believe that adding atezolizumab to chemoradiotherapy could improve the survival of patients with limited-stage small cell lung cancer. NRG-LU005 will compare the usual chemoradiotherapy with the chemotherapy plus atezolizumab to determine if atezolizumab is as good as or better than the usual treatment.

About NRG Oncology
As one of the five research groups in the National Cancer Institute’s (NCI) National Clinical Trials Network (NCTN), NRG Oncology carries out clinical trials on gender-specific malignancies, including gynecologic, breast, and prostate cancers, and on localized or locally advanced cancers of all types.

NRG Oncology’s extensive research organization includes investigators, medical oncologists, radiation oncologists, surgeons, physicists, pathologists, and statisticians. The NRG Oncology includes more than 1,300 research sites worldwide, primarily in the United States and Canada. NRG Oncology is a non-profit research organization, funded mainly through grants from the NCI.

To contact NRG Oncology, call 267-519-6630 or email info@nrgoncology.org.
Frequently Asked Questions

What is a clinical trial?
Clinical trials are research studies that look to find better ways to prevent, diagnose, or treat disease.

Who can join this study?
People who have limited-stage small cell lung cancer that has not spread outside their chest.

Can I change my mind if I choose to take part in this study?
Yes. Taking part in this study is voluntary. If you choose to participate in this study, you are able to leave the study at any time. If you decide not to take part in this study, your doctor will discuss other treatment options with you.

What are the possible study treatments?
Everyone taking part in this study will receive one cycle of chemotherapy before entering the study. On the study, all participants will receive 3 additional cycles of chemotherapy for a total of 4 cycles. Everyone on the study will be randomly assigned to one of two treatment groups. Treatment Group 1 will receive the usual chemotherapy and radiation to treat this type of cancer. Treatment Group 2 will receive the usual chemotherapy and radiation for this type of cancer plus the study drug called atezolizumab.

How long will I be in this study?
The treatment period may last up to one year and participants will be followed for an additional five years after the study treatment ends. After you finish treatment, your doctor will continue to follow your condition every 3 months for 2 years, then they will check in with you every 6 months for 3 years.

Are there side effects?
There may be. Some of the most common side effects of cisplatin, carboplatin, and etoposide chemotherapy include nausea, vomiting, anemia, bruising, bleeding, or infection. Some of the most common side effects of lung radiation include lung inflammation and scarring, esophageal irritation, and fatigue. Some of the most common side effects of atezolizumab that the study doctors know about are tiredness and infection. Atezolizumab may cause side effects in many parts of the body because it increases the immune system response. There may be some side effects of atezolizumab that the study doctors do not yet know about. Your doctor will review all of the potential side effects with you.

More Information
Visit the National Cancer Institute website at https://www.cancer.gov for more information about studies or general information about cancer. You may also call: 1-(800)-4-CANCER (1-800-422-6237)